{
  "ticker": "TYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970853",
  "id": "02970853",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250721",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lz55h5xc8rhh.pdf",
  "summary": "- **Clinical Trial Update**: Patient recruitment commenced for Phase 2a trial assessing TRP-8803 (IV-infused psilocin) for Binge Eating Disorder (BED).  \n- **Trial Details**: 12 patients, two-dose regimen (mid-range and high-range), administered 14 days apart.  \n- **Timing**: First dosing expected Q3 2025; top-line results anticipated Q4 2025.  \n- **Market Potential**: BED is the most common eating disorder in the US and second most prevalent in Australia, representing a significant unmet medical need.  \n\n*No material capital markets or trading-specific information identified.*",
  "usage": {
    "prompt_tokens": 2051,
    "completion_tokens": 134,
    "total_tokens": 2185,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T22:42:01.307325"
}